Article info
PDFExtended reports
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
- Correspondence to:
Dr G Kobelt
European Health Economics SAS, 492 chemin des Laurens, F-06530 Spéracèdes, France; gisela.kobelthe-europe.com
Citation
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
Online issue publication
January 10, 2022
Article Versions
- Previous version (9 January 2022).
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2005 by Annals of the Rheumatic Diseases